Polymyositis Market Analysis
Polymyositis (PM) is a rare idiopathic inflammatory myopathy characterized by symmetric proximal muscle weakness and elevated muscle enzymes. The exact cause of inflammatory myopathy is unclear, and in most cases, the immune system mistakenly attacks healthy body tissues, thus damaging muscle tissue in an autoimmune process.
According to Ann Rheum., the worldwide prevalence is estimated to 5–21.5 per 100,000, but only 3.8 per 100,000 in the US. Similarly, as per the Clark et al., the estimated prevalence is approximately 2 and 8 per 100,000 in Europe with peak Incidence of 60–69 years.
For more details on Polymyositis Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/polymyositis-market
Periodontal Disease Market Analysis
According to The American Academy of Periodontology, “Periodontal Diseases are bacterial gum infections that destroy the gums and supporting bone that holds our teeth in our mouth. Periodontal diseases can affect one tooth or many teeth. The main cause of periodontal diseases is a bacterial plaque which is a sticky, colourless film that constantly forms on the teeth. If the plaque is not removed, it can turn into a hard substance called calculus or tartar in less than two days.
Severe periodontitis is the 6th most prevalent disease worldwide, with an overall prevalence of 11.2% and around 743 million [As per Tonetti et al. 2017]. According to the CDC, the prevalence of periodontitis in the U.S., 47.2% of adults aged 30 years and older have some form of periodontal disease which increases with age. 70.1% of adults 65 years and older have periodontal disease.
For more details on Periodontal Disease Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/periodontal-disease-market
Nicotine Addiction Market Analysis
Nicotine is an addictive substance found in all tobacco products. In addition to being addictive, it is poisonous. Nicotine is a tertiary amine composed of pyridine and a pyrrolidine ring. It is metabolized primarily by the enzyme CYP2A6, and variation in the rate of nicotine metabolism contributes to differences in vulnerability to tobacco dependence and the response to smoking-cessation treatment. Low doses of nicotine can act as a central nervous system stimulant.
Worldwide, tobacco use causes nearly 6 million deaths per year, and current trends show that tobacco use will cause more than 8 million deaths annually by 2030. As per the CDC, ‘Cigarette smoking is responsible for more than 480,000 deaths per year in the United States, including more than 41,000 deaths resulting from secondhand smoke exposure. This is about one in five deaths annually, or 1,300 deaths every day’.
For more detailed information on Nicotine Addiction Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/nicotine-addiction-market
Homocystinuria Market Analysis
HCU is an inherited rare amino acid metabolism disorder in which the body is unable to process amino acid methionine properly leading to an abnormal accumulation of homocysteine and its metabolites in blood and urine. Normally, these metabolites are not found in appreciable quantities in blood or urine.
According to Delveinsight estimates in the year 2017, the total prevalent cases of HCU were 41,684 cases in the 7MM. In 2017, the US accounted for 32,515 prevalent cases (the highest number). These cases are expected to grow with a significant CAGR in the study period.
For more detailed information on Homocystinuria Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/homocystinuria-market-new
Dysmenorrhea Market Analysis
Painful menstrual periods in medical terms are described as Dysmenorrhea, which is often called “menstrual cramps” in simpler terms. Dysmenorrhea can be classified into two types: Primary Dysmenorrhea and Secondary Dysmenorrhea.
As per the Delveinsight, In the year 2017, the total prevalent case of Dysmenorrhea was 134,524,953 cases in the 7MM. The United States, in 2017, accounted for nearly 44% of the total 7MM cases.
Among the EU-5 countries, the highest number of cases of Dysmenorrhea were in Germany, i.e. 13,122,996 cases in the year 2017, which is estimated to rise by the year 2030.
For more information on Dysmenorrhea Market Insights, Epidemiology, and Pipeline Insight, visit:
https://www.delveinsight.com/report-store/dysmenorrhea-market
Alcohol Use Disorder (AUD) Market Analysis
Alcohol use disorder (AUD) is a substance use disorder characterized by excessive, uncontrollable drinking that impacts a person physically, emotionally, and socially. The general population also refers to AUD as alcohol abuse or alcoholism.
As per studies by Psychology Today, 29.1% of the US population has experienced an AUD of a varying grade at some point in their lifetime. Also, in a 1-year period, approximately 13.9% of the US population experience an AUD. Similarly, as per the NHS estimates, “around 9% of men in the UK and 3% of UK women show signs of alcohol dependence”.
For more details on Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/alcohol-use-disorder-market
Acute Lymphoblastic Leukemia (ALL) Market Analysis
Acute lymphocytic leukaemia (ALL), also known as acute lymphoblastic leukaemia, is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts. ALL are caused by a lack of normal circulating blood cells.
As per the Delveinsight, the total incident cases of ALL in the 7MM were observed to be 10,341 cases in 2017 which are expected to grow during the study period (2017–2030). Among the total incident cases of the 7MM; the US accounted for the highest number of cases, i.e., 5,816 cases in 2017. While Japan accounted for around 872 incident cases of ALL in 2017.
For more details on Acute Lymphoblastic Leukemia (ALL) Market Insights, Epidemiology, and Pipeline Insight, visit: https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Acute Ischemic Stroke (AIS) Market Analysis
Acute Ischemic Stroke (AIS) occurs when blood flow through a brain artery is blocked by a clot- a mass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.
As per the study conducted by Edward C Jauch et. al. 2019, nearly 800,000 people suffer from strokes each year in the United States and 82–92% of these strokes are ischemic. Stroke is the fifth leading cause of adult death and disability. While, as per Luciana Catanese et. al. 2017, the incidence of AIS is greater among women beginning with an increased risk in the perimenopausal period and continuing into older age groups.
For more details on Acute Ischemic Stroke (AIS) Market Insights, Epidemiology, and Pipeline Insight, visit: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
Acute Heart Failure (AHF) Market Analysis
Heart Failure (HF), also known as congestive HF, is bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood).
As per Farmakis et al. (2017) AHF constitutes the first reason for hospital admission in the elderly, with a total of approximately one million admissions per year in the US and a similar number in Europe. Similarly, according to the study conducted by Blair et al. (2013), in the US, the incidence of the first hospitalization for AHF is approaching 400 per 100,000 population and is approaching 1,000 per 100,000 population for the second hospitalization.
For more details on Acute Heart Failure (AHF) Market Insights, Epidemiology, and Pipeline Insight, visit:
https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
Lennox-Gastaut Syndrome (LGS) Market
Lennox-Gastaut Syndrome (LGS) is considered as an epileptic encephalopathy and is defined by a triplet of multiple drug-resistant seizure types, a specific EEG configuration presenting bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability.
As per DelveInsight estimates, total diagnosed prevalent cases of LGS in the 7MM was found to be 68,811 in 2017. Among all the countries, the estimates show a higher population of LGS in the United States with 31,925 cases in 2017.
Among the EU5 countries, the UK had the highest diagnosed prevalent population of LGS with 13,082 cases, followed by France. On the other hand, Spain had the lowest prevalent population.
As per DelveInsight estimates, among the 7MM, Japan had the lowest diagnosed prevalent population of LGS in 2017.
For more information on Lennox-Gastaut Syndrome (LGS) Market, visit:
https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market
Value-Based Healthcare Model
Value-based healthcare or VBC is one of the leading concepts in the healthcare domain gaining significant attention from healthcare professionals, providers, and patients. Value-based healthcare addresses various aspects of the healthcare delivery system such as cost, quality, and health outcomes.
Value-based care provides valuable benefits to various stakeholders in healthcare. However, there are many technological, financial, and regulatory challenges in the VBC that hamper its implementation. In the coming years due to higher payer-provider collaboration, adoption of information technology in healthcare, amendment in healthcare policies, organization’s structure, and management approach the VBC is expected to observe a significant growth.
For more detailed information on Value-based healthcare, visit: https://www.delveinsight.com/blog/value-based-healthcare/
Breast Cancer Signs, Symptoms, Causes, Risk Factors, and Treatment Options
Affecting over 2 million women globally every year, Breast Cancer is the most significant cause of death among women. As per the epidemiological forecasts by the end of 2020, around 276,480 women in the United States will be diagnosed with invasive breast cancer. While 48,530 women will be diagnosed with non-invasive (in situ) breast cancer.
Over the years, advancements in technology have significantly improved the treatment of Breast cancer. Generally, a multidisciplinary approach comprising a combination of treatment options depending on type, severity, and stage of Breast cancer is recommended to treat breast cancer. Some of the widely available treatment options for breast cancer include Surgery, Radiation therapy Chemotherapy, Hormone therapy, Targeted therapy, and Immunotherapy.
Apart from the currently available treatment options, several clinical trials are ongoing to bring novel and more efficient treatment options as well as diagnosis methods for patients living with breast cancer.
For more detailed information on breast cancer symptoms causes and treatment, visit: https://www.delveinsight.com/blog/breast-cancer-symptoms-causes-treatment/
Health Disparities
The disparities in the health domain across countries worldwide are quite common. The health disparities are a result of persistent socio-economic disadvantage in healthcare access that a group of people in the country experiences based on their race or ethnicity.
Apart from race and ethnicity, the disparities exist in other dimensions also such as age, sex, sexual orientation, disability status, geographic location, socio-economic status, and others where the differences in access to healthcare can be observed. The health disparity is a hurdle for the country to achieve good health for its citizens.
For more detailed information on Health Disparities, visit: https://www.delveinsight.com/blog/health-disparities/
Schizophrenia Market
The Schizophrenia market is expected to increase with a CAGR of 6.89% for the study period 2017-2030 (in 7MM).
Schizophrenia affects approximately 20 million people worldwide. Around 30% of Schizophrenia patients are resistant to available antipsychotic drugs.
To bridge the broadening gaps in the treatment of Schizophrenia, several pharma and biotech companies such as Alkermes, Avineuro Pharma, Inc., Boehringer Ingelheim, Newron Pharma, Acadia Pharma, Minerva Neurosciences, BioXcel Therapeutics, Acadia Pharma, among several others are investigating their novel therapies.
For more details on Schizophrenia Market, visit: https://www.delveinsight.com/blog/schizophrenia-market/
Non-Muscle Invasive Bladder Cancer (NMIBC) Market
The Non-Muscle Invasive Bladder Cancer (NMIBC) Market is anticipated to surge with a CAGR of 8% during the study period 2017-2030. There are several unmet needs in the NMIBC market, and no approved therapy to offer relief to the patients.
To address the unmet needs, several pharma and biotech companies were, and still are trying hard, with novel promising agents including gene therapies and fusion proteins in their pipeline.
The NMIBC Market is going to experience a significant boost in the coming years owing to several factors ranging from the strong pipeline to an increase in prevalence.
For more details, visit: https://www.delveinsight.com/blog/nmibc-market-drivers-and-barriers/
Opioid Crisis
As per the World Health Organization, worldwide, around 0.5 million deaths are attributable to drug use. More than 70% of these deaths are related to opioids, with more than 30% of those deaths caused by overdose.
To tackle the Opioid epidemic, some of the key pharma and biotech companies such as Purdue Pharma, Orexo US, Indivior, Adapt Pharma, Aphios Corporation, Camurus, GW Pharmaceuticals, MediciNova, and others are developing therapies for the treatment of opioid overdose, dependency, and addiction.
For more details on Opioid Crisis, visit: https://www.delveinsight.com/blog/opioid-epidemic/
The Fight Against Genetic Disorders in Arab Population
To curb the growing incidence of recessive genetic disorders in the region, the MENA countries have taken several steps. From an inclination towards adopting technologies to diagnose and rectify the genetic mutations to the approval of gene therapies to correct the disorder, the governments in the region are greatly focusing towards addressing the problem of the rising prevalence of genetic disorders.
For more details, visit: https://duphat.ae/The+Fight+Against+Genetic+Disorders+in+Arab+Population
UAE’s-Booming-Investment-In-The-Healthcare-Space
The healthcare sector in the UAE region is experiencing significant growth. From harnessing the power of Artificial Intelligence in healthcare to leveraging the robots for the dispensing of prescription drugs, UAE is doing it all to reinvent the healthcare system.
To equip its healthcare sector with Smart Hospitals the UAE government has partnered with some of the major US medical device giants such as GE Healthcare, Philips, Abbott, 3M, and Medtronic.
Rapid urbanization of the country, demographic shift, modernization of people’s lifestyle, looming burden of chronic lifestyle disease, and the demand for value-based healthcare in the region are expected to provide momentum to the healthcare sector in the coming years.
To read more, visit:
https://duphat.ae/uaes-booming-investment-in-the-healthcare-space/
Osteosarcoma Therapeutics Market Analysis
As per DelveInsight’s analysis, the Osteosarcoma therapeutic market in the 7MM was estimated to be USD 72.50 million in 2017 and is further expected to increase modestly in the forecast period 2020-30.
Worldwide, some of the key companies such as Eisai, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GSK, Novartis, AADi Bioscience, Eleison Pharmaceuticals, Aurora BioPharma, BioAtla, Iovance Biotherapeutics, Bristol Myers Squibb, Cellestia Biotech are actively engaged in producing desirable pipeline therapies.
For more details on Osteosarcoma Therapeutics Market, visit: https://www.delveinsight.com/blog/osteosarcoma-market-key-pharma-companies/
Osteosarcoma Treatment Market Analysis
Osteosarcomas are rare, yet are the leading cause of deaths due to cancer in the pediatric population. It is a high-grade malignancy of mesenchymal origins. They are the most frequent forms of primary bone tumors and account for approximately 20% of all the bone tumors. With the incident population of less than 2500 in the 7MM (the US, EU5 (the UK, Germany, France, Italy, and Spain), and Japan)in 2017, the rarity of Osteosarcomas makes its management quite bone-breaking.
To bridge the treatment gaps, many pharma, and biotech companies in the Osteosarcoma treatment market including EISAI LIMITED, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GSK, Novartis, AADi Bioscience, Eleison Pharmaceuticals, Aurorabiopharma, BioAtla, Iovance Biotherapeutics, Bristol Myers Squibb, Cellestia Biotech, among others are developing novel therapeutic strategies.
For more details on Osteosarcoma Treatment Market, visit: https://www.delveinsight.com/blog/osteosarcoma-treatment-market/
Joined Feb 2020
